Investor Updates

May 24, 2013
Roche Analyst Event at ASCO 2013
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products ... more

May 24, 2013
Launch of Subcutaneous Injection formulation, Actemra, for treatment of Rheumatoid Arthritis in Japan
more

May 22, 2013
Roche presents new, fully automated lab solution at Europe's largest diagnostics conference
Roche announced today at the IFCC Euromedlab in Milan, Italy that it will soon introduce the cobas 8100 automated workflow ... more

May 18, 2013
Roche's etrolizumab meets primary endpoint of clinical remission in moderate to severely active ulcerative colitis at week 10
Roche announced today that the EUCALYPTUS phase II induction study of etrolizumab in patients with moderate-to-severely active ... more

May 16, 2013
Roche to present data on investigational cancer immunotherapy anti-PDL1 antibody MPDL3280A at ASCO 2013
Roche today announced that the company will present important new data on its anti-PDL1 antibody MPDL3280A (also known as ... more

May 16, 2013
Roche's obinutuzumab (GA101) significantly reduced the risk of disease progression or death in people with one of the most common forms of blood cancer
Roche today announced the first results from CLL11, a phase III study of the investigational medicine GA101 which is being ... more

May 15, 2013
FDA approves Tarceva (erlotinib) tablets and cobas EGFR Mutation Test for specific type of lung cancer
Tarceva is the first personalised medicine approved for the initial treatment of people with EGFR mutation-positive advanced ... more

May 15, 2013
Roche to present important new data reflecting broad cancer pipeline at ASCO
Roche today announced that important new data from clinical trials of several investigational and approved cancer medicines ... more

May 02, 2013
Roche Analyst Event at ASCO 2013
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group’s oncology products ... more

April 30, 2013
FDA approves ACTEMRA for children living with a rare form of arthritis
Roche announced today that the U.S. Food and Drug Administration (FDA) has approved ACTEMRA (tocilizumab) for the treatment ... more

April 26, 2013
CHMP recommends conditional EU approval of Roche's Erivedge for advanced basal cell carcinoma, a rare but potentially devastating form of skin cancer
Roche announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has recommended ... more

April 26, 2013
Roche gains CHMP positive opinion for RoACTEMRA for children living with a rare form of arthritis in Europe
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ... more

April 23, 2013
Roche to change Applied Science business structure
Roche today announced changes to the management and set-up of its life-science business. The Applied Science Business Area ... more

April 11, 2013
Roche Group posts strong sales growth in the first quarter
Group sales increase 6% at CER to 11.6 billion Swiss francs; Pharmaceuticals sales rise 7% to 9.2 billion Swiss francs, driven ... more

April 04, 2013
Reminder: Invitation to Roche's First Quarter Sales 2013 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2013 prior to the opening of the Swiss Stock Exchange on Thursday ... more

March 25, 2013
Actemra, a Treatment for Rheumatoid Arthritis Obtained Approval for Subcutaneous Injection Formulation
Dear Investor, Please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. more

March 21, 2013
Roche adopts IAS19 (revised) and implements presentational changes with effect from 1 January 2013
Change in the accounting policy - IAS 19 (revised) Employee Benefits. Presentational change - Pharmaceuticals Division geographic ... more

March 18, 2013
Roche's Pegasys receives EU approval for the treatment of chronic hepatitis C in children five years of age and older
Roche announced today that the European Medicines Agency (EMA) has expanded the approval of Pegasys (peginterferon alfa-2a) ... more

March 11, 2013
Invitation to Roche's First Quarter Sales 2013 Conference Call
Thursday April 11th, 2013 - 14:00 CEST. Roche will publish its Sales Results for the 1st Quarter of 2013 prior to the opening ... more

March 06, 2013
FDA approves new Roche test to evaluate response to hepatitis C therapy
Viral load test uses a novel dual-probe approach designed to manage patients being treated with antiviral therapies. Roche ... more

March 05, 2013
Roche Annual General Meeting 2013
Roche announced today that its Ordinary Annual General Meeting voted in favour of all the Board of Directors' proposals. ... more

March 05, 2013
Roche Chairman Franz B. Humer announces that he will not stand for re-election in 2014
Franz B. Humer, Chairman of the Board of Directors of the Roche Group, announced at today’s Annual General Meeting that ... more

March 05, 2013
Roche obtains EU approval for PERJETA, a new personalised treatment for aggressive type of breast cancer
Roche today announced that the European Medicines Agency (EMA) has approved PERJETA(pertuzumab) for patients with previously ... more

February 22, 2013
FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla (trastuzumab emtansine or T-DM1) ... more

February 18, 2013
Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin for acromegaly and neuroendocrine tumors
Roche and Chiasma (pronounced key-azma) Inc., a privately held biopharma company, announced today that they have entered into ... more

January 31, 2013
Obinutuzumab (GA101) significantly improved progression-free survival in people with chronic lymphocytic leukemia (CLL)
Roche today announced positive results from stage 1 of CLL11, a phase III randomised study to investigate the efficacy and ... more

January 30, 2013
Full reconciliation of Chugai 2012 results into IFRS
Results of Chugai as consolidated by the Roche Group more

January 30, 2013
Roche delivers strong 2012 results
Group sales rise 4% to 45.5 billion Swiss francs due to oncology sales, clinical laboratory business; Core EPS 10% higher ... more

January 29, 2013
New Drug Application Filed for Antibody-Drug Conjugate
Trastuzumab Emtansine for the Treatment of HER2-Positive Metastatic or Recurrent Breast Cancer more

January 24, 2013
FDA approves new use of Avastin plus chemotherapy for people with metastatic colorectal cancer
Roche today announced that the US Food and Drug Administration (FDA) has approved a new use of Avastin (bevacizumab) in combination ... more

January 21, 2013
Reminder: Invitation to Roche's Full Year Results for 2012
Roche will publish its Full Year Results for 2012 prior to the opening of the Swiss Stock Exchange on 30 January 2013, 7:00 ... more

January 15, 2013
Change to the Roche Corporate Executive Committee
Roche today announced that John C. Reed, M.D., Ph.D., has been appointed Head of Roche Pharma Research and Early Development ... more

January 02, 2013
Invitation to Roche's Full Year Results for 2012
Roche will publish its Full Year Results for 2012 prior to the opening of the Swiss Stock Exchange on 30 January 2013. more